Forte Biosciences
FBRX
FBRX was delisted on the 26th of August, 2026.
47 hedge funds and large institutions have $330M invested in Forte Biosciences in 2020 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 5 closing their positions.
400% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 5
363% more capital inflows, than outflows
Capital inflows: $133M | Capital outflows: $28.6M
74% more funds holding
Funds holding: 27 → 47 (+20)
33.99% more ownership
Funds ownership: 26.71% → 60.7% (+34%)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$77.9M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$25.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$9.03M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$4.79M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$16.2M |
| 2 |
FAM
Fred Alger Management
New York
|
-$6.85M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$5.34M |
| 4 |
MA
MYDA Advisors
Woodmere,
New York
|
-$159K |
| 5 |
TAM
Tocqueville Asset Management
New York
|
-$58.3K |
FBRX Hedge Fund Activity: Q3 2020 in Review
47 of the 4,972 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q3 2020, worth a combined $330M — up 685% from $42.1M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new FBRX positions and 5 closed out — a net gain of 20 holders — while 9 added to existing stakes and 9 trimmed.
The largest buyer was ArrowMark Colorado Holdings, opening a new position worth an estimated $77.9M. The largest seller was OrbiMed, cutting an estimated $16.2M.
- 47 institutional investors held Forte Biosciences (FBRX) as of Q3 2020, up from 27 in Q2 2020.
- Funds reported $330M of Forte Biosciences stock for Q3 2020, up 685% quarter-over-quarter.
- 25 funds opened new Forte Biosciences positions in Q3 2020 and 5 closed out, a net change of +20 holders.
- The largest Forte Biosciences buyer in Q3 2020 was ArrowMark Colorado Holdings, an estimated $77.9M added.
- The largest Forte Biosciences seller in Q3 2020 was OrbiMed, an estimated $16.2M sold.
Based on aggregated 13F filings for Q3 2020.